novo nordisk patent semaglutide Semaglutide's expires today. What does it mean for patients, pharma players and Nordisk? EPO revokes another Novo Nordisk
Description
KB Contract Pharma: How are stakeholders ensuring the quality and supply chain security of existing product so what is available remains viable and accessible for patients
Bioavailability: the critical limitation Here is where the conversation gets real
The Road towards Triple agonists: Glucagon-Like peptide 1, glucose-dependent Insulinotropic polypeptide and glucagon Receptor-An update
Some patients respond better to one over the other
What makes this interesting is that it appears to be reported more often with Retatrutide than with older GLP-1 drugs
doi: 10.1111/obr.13535
